<DOC>
	<DOCNO>NCT00002718</DOCNO>
	<brief_summary>RATIONALE : Bone marrow peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness T-cell deplete bone marrow G-CSF stimulate peripheral stem cell transplantation treat patient leukemia , lymphoblastic lymphoma , myelodysplastic syndrome , aplastic anemia .</brief_summary>
	<brief_title>T-cell Depleted Bone Marrow G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors Treating Patients With Leukemia , Lymphoblastic Lymphoma , Myelodysplastic Syndrome , Aplastic Anemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine potential T-cell-depleted bone marrow peripheral blood stem cell ( PBSC ) HLA-haplotype , partially match related donor induce extend disease-free survival patient leukemia , lymphoblastic lymphoma , myelodysplastic syndrome , severe aplastic anemia would otherwise ineligible transplantation lack HLA-identical relate unrelated donor . - Determine impact filgrastim ( G-CSF ) -stimulated , CD34+ , E-rosette T-cell-depleted PBSC derive HLA-haplotype , partially match donor incidence quality engraftment , kinetics , quality hematopoietic immunologic reconstitution , incidence severity graft-versus-host disease ( GVHD ) patient . - Correlate dos PBSC clonable T-cells incidence engraftment , extent chimerism , incidence severity acute chronic GVHD , characteristic hematopoietic immunologic reconstitution , overall disease-free survival rate 2-4 year transplantation patient . OUTLINE : Patients stratify number HLA-incompatible allele ( 1 vs 2 3 ) . - Harvest : Beginning 6-10 day transplantation , allogeneic bone marrow harvest treated vitro . Beginning 5-6 day transplantation , filgrastim ( G-CSF ) -stimulated , allogeneic peripheral blood stem cell ( PBSC ) harvest , select CD34+ cell , treat vitro . If feasible , autologous bone marrow harvest event allogeneic graft failure . - Myeloablation : Patients undergo total body irradiation 3 time day day -9 -6 , thiotepa IV 4 hour day -5 -4 , cyclophosphamide IV day -3 -2 . - Transplantation : CD34+ , E-rosette T-cell-depleted PBSC infuse 15 minute T-cell-depleted bone marrow infuse 1-5 minute day 0 . Patients receive G-CSF IV 30 minute begin day 1 continue blood count recover taper . Patients receive anti-thymocyte globulin IV 4-6 hour day 8 , 10 , 12 , 14 oral methylprednisolone day 8-14 follow tapered dos day 15-17 . - CNS prophylaxis : Beginning least 2 month transplantation , patient acute lymphocytic leukemia ( ALL ) history CNS leukemia receive cytarabine intrathecally ( IT ) monthly 6 month patient ALL history CNS leukemia receive cytarabine IT monthly 12 month . Patients graft failure offer autologous bone marrow transplantation ( BMT ) second allogeneic BMT . Patients follow 1 , 3 , 6 , 12 month annually 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Acute myelogenous leukemia ( AML ) meet 1 follow condition : Failed achieve first remission intensive induction regimen contain anthracycline cytarabine In second remission enrol protocol autologous bone marrow transplantation Failed achieve sustain second remission In first remission high risk relapse 1 follow factor : Highrisk cytogenetic feature ( monosomy 7,5q , trisomy 8 , ( 9 ; 22 ) ) AML secondary treatment prior malignancy without goodrisk cytogenetic feature ( 8 ; 21 ) , ( 15 ; 17 ) , inv 16 AML secondary myelodysplastic disease Acute lymphocytic leukemia ( ALL ) meet 1 follow condition : In second remission initial relapse occur within 2 year diagnosis In first complete remission highrisk cytogenetics ( ( 9 ; 22 ) ( 4 ; 11 ) ) In third subsequent remission Failed achieve sustain second remission Chronic myelogenous leukemia ( CML ) first second chronic phase accelerate phase Stage IV lymphoblastic lymphoma first remission fail achieve remission within first 4 week induction therapy Juvenile CML Myelodysplastic syndrome Severe aplastic anemia unresponsive antithymocyte globulin cyclosporine No CNS skin involvement leukemia No requirement mediastinal irradiation No healthy , HLAidentical relate donor least 1 year age match unrelated donor available within 46 month Availability healthy , 13 HLAA , B , DR mismatch related donor Willing able undergo general anesthesia marrow donation 5day course filgrastim ( GCSF ) 2 daily leukaphereses PATIENT CHARACTERISTICS : Age : Under 50 ( 50 allow casebycase basis ) Performance status : Age 16 : Karnofsky 70100 % Under age 16 : Lansky 50100 % Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL ( absence liver involvement ) AST less twice normal ( absence liver involvement ) Renal : Creatinine normal OR Creatinine clearance great 60 mL/min Cardiovascular : Asymptomatic LVEF great 50 % rest , improvement exercise Pulmonary : Asymptomatic DLCO great 50 % predict ( correct hemoglobin ) Other : No known hypersensitivity mouse protein chicken egg product No active viral , bacterial , fungal infection HIV1 , HIV2 , HTLV1 , HTLV2 negative No concurrent medical condition would preclude transplantation Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>